GNAQ-/GNA14-mutated hepatic vascular malformation with capillary proliferation in adults and children

Anne Kristin Fischer1, Carina Heydt1, Janna Siemanowski-Hrach1

  • 1Institute of Pathology, University of Cologne, Kerpener Str. 62, 50937, Germany.

Human Pathology
|September 14, 2025
PubMed

Insights

Congenital hepatic vascular malformation with capillary proliferation (HVMCP) is a rare liver lesion. Driver mutations in GNAQ/GNA14 were identified, suggesting potential targeted therapies for HVMCP.

Area of Science:

  • Hepatology
  • Vascular Biology
  • Oncology

Background:

  • Congenital hepatic vascular malformation with capillary proliferation (HVMCP) is a rare, pseudo-tumorous liver lesion.
  • Previously, HVMCP was exclusively documented in pediatric patients.

Purpose of the Study:

  • To histomorphologically characterize diagnostic pitfalls of HVMCP in infants and adults.
  • To perform molecular analysis for driver mutations involved in angiogenesis and angioproliferation in HVMCP.

Main Methods:

  • Histomorphological characterization of 6 HVMCP cases (4 infant, 2 adult).
  • Analysis of CD34 and GLUT1 expression.
  • Custom hybrid-capture-based sequencing for angiogenesis and angioproliferation genes.
  • GNAQ/GNA14 mutation analysis.

Main Results:

  • HVMCP cases exhibited malformed CD34-positive, GLUT1-negative capillaries and trabecular disarrangement.
  • Infant HVMCP mimicked hepatoblastoma; adult HVMCP resembled hepatocellular carcinoma or small vessel neoplasia.
  • Pathogenic GNAQ/GNA14 driver mutations were found in 3 cases, including one adult.

Conclusions:

  • HVMCP requires differentiation from vascular neoplasms and malignant hepatocellular tumors.
  • Recognizing the vascular malformation is key to identifying HVMCP's pseudotumorous nature.
  • GNAQ/GNA14 mutations and MAPK/ERK pathway activation suggest potential targeted therapy with MAPK/ERK inhibitors for non-resectable HVMCP.
Abstract